Samrat Pharmachem has scheduled its 34th Annual General Meeting (AGM) for Wednesday, September 23, 2026. The meeting will be conducted through Video Conferencing or Other Audio Visual Means at 1:00 pm.

The company announced the closure of its Register of Members and Share Transfer books from Sunday, September 20, 2026, to Tuesday, September 22, 2026. This period coincides with the remote e-voting window. Voting rights are determined by equity holdings as on Wednesday, September 16, 2026.

Voting Schedule

Shareholders can cast their votes electronically during the specified dates via MUFG Intime India Private Limited. The timeline is as follows:

Members who have cast their vote by remote e-voting prior to the AGM may also attend or participate in the AGM through VC/OAVM but shall not be entitled to cast their vote again. Those present in the AGM who had not cast votes remotely are eligible to vote during the meeting.

For technical issues regarding Insta Vote e-voting, members may refer to the FAQs available at the MUFG Intime website or contact the investor relations helpdesk at +918108116767.

Document Availability

The Annual Report for the financial year 2025-26, containing the notice for the meeting, is available on the company’s website. Nishant Kankaria, Company Secretary and Compliance Officer, signed the communication to the BSE Limited on August 27, 2026.

Members holding physical securities must update their KYC as per SEBI guidelines to receive dividends.

Samrat Pharmachem reported a return to profitability in its standalone results for the first quarter of FY27, posting a net profit of ₹87.60 lakh for the period ended June 30, 2026. This marks a significant turnaround from the previous quarter, where the company recorded a net loss of ₹203.63 lakh.

The pharmaceutical chemicals manufacturer saw its total income from operations rise to ₹7,976.10 lakh in Q1FY27, up from ₹7,565.16 lakh in the same period last year. The improvement in top-line performance helped the company generate a profit before tax of ₹158.53 lakh, compared to a pre-tax loss of ₹187.33 lakh in Q4FY26.

Financial Performance

The company’s financial metrics for the quarter and the preceding periods are detailed below:

For the full fiscal year ended March 31, 2025, Samrat Pharmachem reported a net loss of ₹331.20 lakh on total income of ₹28,972.12 lakh. The basic earnings per share for Q1FY27 stood at ₹2.84, improving from a loss of ₹6.59 per share in the previous quarter.

What the Numbers Show

The divergence between revenue growth and profit realization highlights the volatility in the company's operational efficiency during this period. While revenue grew modestly by approximately 5.4% year-on-year, the shift from a pre-tax loss of ₹187.33 lakh in Q4FY26 to a pre-tax profit of ₹158.53 lakh in Q1FY27 indicates a sharp correction in cost management or pricing dynamics. However, with no exceptional items disclosed, the entire profit reversal is attributable to core operational improvements rather than one-off gains.

The Board of Directors approved the unaudited standalone financial results in a meeting held on August 14, 2026, at the company’s corporate office in Mumbai. The results were reviewed by the Audit Committee prior to board approval.